Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.

J Immunother Cancer · 2019 · PMC6419437 · PMID 30871628

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

showed a trendp = 0.10so close (0.05 < p ≤ 0.1)

non-maintenance showed a trend toward improved TTRF ( p = 0.10, Fig. 3 a), improved duration of response ( p < 0.001, Fig. 3 b), and a trend toward improved % tumor shrinkage ( p = 0.08, Fig. 3 c).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.